Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from KALA BIO ( (KALA) ).
KALA BIO has scheduled its next annual meeting of stockholders for January 30, 2026, with stockholder proposals due by December 27, 2025. The company has entered into a Convertible Loan Agreement and a Securities Purchase Agreement with David Lazar, resulting in a $375,000 loan and a $6.0 million private placement of preferred shares. David Lazar has been appointed as CEO and a director, and he has sold his rights to purchase Series AAA Preferred Shares to AK Holdings Group Inc., retaining his Series AA shares and loan agreement.
The most recent analyst rating on (KALA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on KALA BIO stock, see the KALA Stock Forecast page.
Spark’s Take on KALA Stock
According to Spark, TipRanks’ AI Analyst, KALA is a Underperform.
Kala Pharmaceuticals faces significant financial difficulties, marked by declining revenues and heavy reliance on debt, which pose serious risks. The technical analysis reflects a strong downtrend, with the stock being oversold, adding to the negative outlook. Valuation is unattractive due to negative earnings and the lack of a dividend, further weighing down the stock’s appeal.
To see Spark’s full report on KALA stock, click here.
More about KALA BIO
Average Trading Volume: 7,890,806
Technical Sentiment Signal: Sell
Current Market Cap: $7.24M
Learn more about KALA stock on TipRanks’ Stock Analysis page.